Anlon Healthcare Limited has successfully completed its strategic acquisition of Apiqo Organics Private Limited, marking a significant milestone in the company's expansion strategy. The pharmaceutical company announced the completion of acquiring a 67.48% equity stake in the target company on January 9, 2026.

Acquisition Details

The acquisition was executed in accordance with the Share Purchase Agreement (SPA) dated December 2, 2025, which was previously disclosed to the stock exchanges. Following the completion of this transaction, Apiqo Organics Private Limited has become a subsidiary of Anlon Healthcare Limited.

Regulatory Compliance

The investment and acquisition transaction has been structured in full compliance with applicable regulatory requirements. The company confirmed that the acquisition adheres to Section 179(3)(e) & (j) and all other applicable provisions of the Companies Act, 2013.

The disclosure was made pursuant to Regulation 30(7) read with Para A of Part A of Schedule III of the SEBI Listing Regulations. This follows the company's earlier intimation dated December 2, 2025, regarding the execution of the Share Purchase Agreement.

Corporate Structure Impact

With the completion of this acquisition, Anlon Healthcare has expanded its corporate structure through the addition of Apiqo Organics as a subsidiary. The target company was formerly known as M/s Apple Life Science, operating as a partnership firm before its transformation into a private limited company.

The transaction details, as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, were previously provided in the December 2, 2025 disclosure to ensure complete regulatory transparency.

Management Authorization

The acquisition completion was formally communicated to both BSE Limited and The National Stock Exchange of India Ltd by Managing Director Punitkumar Rasadia, who digitally signed the disclosure document on January 9, 2026. The communication ensures that all stakeholders and regulatory bodies are informed of this significant corporate development in accordance with listing obligations.

Anlon Healthcare Limited has announced plans to establish a new marketing office in Ahmedabad, Gujarat, marking a significant step in the company's expansion strategy. The announcement was made through a regulatory filing under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Business Expansion Details

Anlon Healthcare Limited disclosed its intention to open the marketing office in Ahmedabad in the near future, though specific timelines were not provided in the announcement. This expansion move appears to be part of the company's strategy to strengthen its market presence in the Gujarat region.

Regulatory Compliance

The disclosure was made in compliance with the listing regulations, demonstrating Anlon Healthcare's commitment to maintaining transparency with stakeholders and regulatory authorities. The company has assured that it will provide further updates as developments progress regarding this new facility.

Company Background

Anlon Healthcare Limited operates in the chemicals sector and is registered in Gujarat. The company's registered office is located at 101/102, Silver Coin Complex, Opp. Crystal Mall, Kalawad Road, Rajkot-360005, Gujarat. Anlon Healthcare maintains its commitment to keeping stakeholders informed about significant business developments through proper regulatory channels.

The establishment of a marketing office in Ahmedabad represents the company's strategic focus on expanding its operational footprint within Gujarat, potentially enhancing its market reach and customer engagement capabilities in the region.